24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

Recruiting now · Phase 2

Conditions studied: Pancreas Adenocarcinoma

In brief

The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.

Key facts

Study ID

NCT07043270

Run by

Dartmouth-Hitchcock Medical Center

People needed

35

Starts

2025-09-29

Expected to finish

2029-07-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Diagnosis of BR-PDAC. The resectability should be officially determined with surgical oncologists at the Dartmouth Cancer Center (DCC) GI multidisciplinary Tumor Board based on NCCN Guidelines Version 2.2024 Pancreatic Adenocarcinoma.
• Patients must be able and willing to provide informed consent.
• Contrast-enhanced CT scan of the chest, abdomen, and pelvis performed within 45 days before registration.
• ECOG Performance Status: 0-1.
• Females of childbearing potential must have a negative pregnancy test done ≤ 14 days prior to study enrollment, and must agree to use a highly effective method of contraception throughout the course of protocol therapy.

You may not qualify if…

• Any prior receipt of chemotherapy or radiation therapy for PDAC.
• Known DPYD poor metabolizer genotype.
• Known BRCA1/2 or PALB2 mutations. If they are found to have BRCA1/2 or PALB2 mutation after inclusion to the trial, the participant will be taken off of protocol therapy (since platinum-containing therapy is preferred for these patients).
• Any confirmed second malignancy that is likely to require systemic therapy during the study period, in the opinion of the enrolling investigator.
• Any of the following baseline laboratory abnormalities:
• Absolute neutrophil count (ANC) < 2,500/mm3
• Platelet count < 100,000/mm3
• Hemoglobin < 7 g/dL
• Creatinine > 1.5 x upper limit of normal (ULN)
• Total bilirubin > 1.5 x ULN
• AST/ALT > 5 x ULN
• Any peripheral sensory neuropathy that meaningfully impairs performance of instrumental activities of daily living, as evaluated by the enrolling investigator.
• Patients who are unable to provide informed consent.
• Patients who are pregnant or breastfeeding.
• Patients who are incarcerated.

Where it is running

• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.